Solid-Phase Peptide Synthesis Selective Deprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for producing glucagon (Gcg) and GLP-1 dual agonist peptides face challenges such as low yield, purity issues, and the need for harsh reaction conditions, which complicates large-scale production and purification, and there is a requirement for more efficient and environmentally friendly methods.
Innovation Solution
A novel process involving solid-phase synthesis with selective deprotection and acylation of lysine at position 20 using a chemically modified epsilon-amino group, combined with specific side-chain protecting groups like ivDde and Alloc, to achieve high yield and purity with fewer purification steps and reduced resource intensity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional peptide synthesis processes are used, then production capacity is achieved, but yield and purity are low requiring harsh reaction conditions and extensive purification
Solution Approach 1:
The patent applies preliminary action by introducing base-stable protecting groups (PG1) during solid-phase synthesis that remain intact during base-mediated deprotection steps. This pre-protection strategy prevents premature side reactions and ensures high purity of the final product without requiring harsh purification conditions, thereby resolving the contradiction between purity and yield
2Manufacturing precision
If selective deprotection and acylation at Lys-20 is performed, then purity is improved, but process complexity increases
Solution Approach 1:
The patent applies local quality by using different protecting groups with distinct stability characteristics at different positions: base-stable protecting groups (PG1) at most positions versus base-labile ivDde/Dde/Alloc groups at Lys-20. This localized differentiation enables selective deprotection and acylation at Lys-20 while maintaining simplicity in other regions, improving purity without excessive complexity
3Productivity
If base-stable side-chain protecting groups are used, then fewer purification steps are needed, but synthesis conditions become more restrictive
Solution Approach 1:
The patent applies parameter changes by selecting protecting groups with specific base stability parameters. The base-stable protecting groups (PG1) are designed to withstand the basic conditions used for deprotection of ivDde/Dde/Alloc groups at Lys-20. This parameter optimization allows the synthesis to proceed under unified basic conditions without requiring additional purification steps, resolving the contradiction between productivity and ease of manufacture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process results in a Gcg and GLP-1 dual agonist peptide with improved yield, purity, and reduced environmental impact, facilitating more efficient and commercially viable production.
Implementation Method 1
cleavage of the compound from the solid support
Implementation Method 2
purification of the compound
Data Source
AI summary
The present invention provides processes and compounds for the preparation of glucagon and GLP-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).